Medicinal applications of heavy-metal compounds

Current Opinion in Chemical Biology

Volumn 3, Issue 2, 1999, Pages 236-240

  Reedijk, Jan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BBR 3464; CIS AMMINEDICHLORO(2 METHYLPYRIDINE) PLATINUM(II); CISPLATIN; GADOLINIUM; GADOTERIC ACID; HEAVY METAL; OXALIPLATIN; PLATINUM DERIVATIVE; RUTHENIUM DERIVATIVE; TECHNETIUM 99M; TECHNETIUM DERIVATIVE; UNCLASSIFIED DRUG;

REVIEW;

EID: 0033120927     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80037-4     Document Type: Article

References (44)

1. Reedijk J: Improved understanding in platinum antitumour chemistry. Chem Comm 1996:801-806.
2. di Blasi P, Bernareggi A, Beggiolin G, Piazzoni L, Menta ER, Formento ML: Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinum complex BBR 3464 in sensitive- and cisplatin-resistant murine leukemia cells. Anticancer Res 1998, 18:3113-3118. This is the first, full paper on a new class of compounds that very rapidly made its way to clinical trials.
3. Qu YN, Boemink MJ, Reedijk J, Hambley TW, Farrell N: Dinuclear platinum complexes form novel intrastrand adducts with d(GpG), an anti-syn conformation of the macrochelate as observed by NMR and molecular modeling. J Am Chem Soc 1996, 118:9307-9313.
4. Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, Abrams M, Kelland LR: Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis[amminedichloro(Z-methylpyridine)]platinum(II) (AMD473). Anticancer Drug Des 1998, 13:1-18. This paper introduces a new drug that has been designed to have slower in vivo reactions.
5. Bleiberg H: Oxaliplatin (I-OHP): A new reality in colorectal cancer. Br J Cancer 1998, 77(suppl 4):1 -3.
6. Chen Y, Guo Z, Parkinson JA, Sadler PJ: Kinetic control of reactions of a sterically hindered platinum picoline anticancer complex with guanosine 5-monophosphate and glutathione. J Chem Soc Dalton Trans 1998:3377-3385. A good kinetic and mechanistic analysis, explaining the slowed-down reactivity of this drug compared to cisplatin.
7. Misset J-L: Oxaliplatin in practice. Br J Cancer 1998, 77(suppl 4):4-7.
8. Yang D, Van Boom SSGE, Reedijk J, van Boom JH, Wang AHJ: Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. Biochemistry 1995, 34:12912-12920.
9. Gelasco A, Lippard SJ: NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 1998, 37:9230-9239.
10. Takahara PM, Rosenzweig AV, Frederick CA, Lippard SJ: Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 1995, 377:649-652.
11. Takahara PM, Frederick CA, Lippard SJ: Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J Am Chem Soc, 1996, 118:12309-12321.
12. Yang D, van Boom SSGE, Reedijk J, van Boom JH, Farrell NH, Wang AHJ: A novel DNA structure induced by the anticancer bisplatinum compound crosslinked to a GpC site in DNA. Nat Struct Biol 1995, 2:577-586.
13. Ohndorf U-M, Whitehead J-P, Raju NL, Lippard S-J: Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatinDNA adducts. Biochemistry 1997, 36:14807-14815.
14. Smith JF, Bowman A, Perren T, Wilkinson P, Presciott RJ, Quinn KJ, Tedeschi M: A phase II trial of carboplatin and etoposide for relapse or metastatic carcinoma of cervix. Ann Oncol 1997, 8:569-574.
15. 7.
16. Guo Z, Hambley TW, del S. Murdoch P, Sadler PJ: Chelate-ring-opened adducts of [Pt(en)(Me-Mal-O, O′)] (en equals ethane-1,2-diamine, Me-Mal equals 2-methylmalonate) with methionine derivatives: Relevance to the biological activity of platinum anticancer agents. J Chem Soc Dalton Trans 1997:469-478.
17. 7.
18. Budd GT, Ganapathi R, Adelstein DJ, Pelly R, Olencki T, Petrus J, McLain D, Zhnag J, Capizzi R, Bukowski RM: Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997, 80:1134-1140.
19. Roat RM, Jerardi MJ, Kopay CB, Heath DC, Clark JA, DeMars JA, Weaver JM, Bezemer E, Reedijk J: Platinum(II) complexes catalyze reactions between platinum(IV) complexes and 9-methylxanthine. J Chem Soc DaltonTrans 1997:3615-3362. This paper shows that Pt(IV) species might be useful as intermediates and prodrugs.
20. Talman EG, Kidani Y, Mohrmann L, Reedijk J: Can Pt(IV) -amine complexes act as 'prodrugs'? Inorg Chim Acta 1998, 283:251-255.
21. Dunham SU, Lippard SJ: DNA Sequence context and protein composition modulate HMG-Domain protein recognition of cisplatin-modified DNA. Biochemistry 1997, 36:11428-436. The ultimate action of cell kelling requires at least a protein surrounding the platinated DNA.
22. BernersPrice SJ, Corazza A, Guo Z, Barnham KJ, Sadler PJ, Ohyama Y, Leng M, Locker D: Structural transitions of a GG-platinated DNA duplex induced by pH, temperature and box A of high-mobility-group protein. Eur J Biochem 1997, 243:782-791.
23. Zamble DB, Jacks T, Lippard SJ: p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA 1998, 95:6163-68. This paper provides good evidence for a key role of p53 in the cisplatin mechanism.
24. Ishibashi T, Lippard SJ: Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci USA 1998, 95:4219-4223. An exciting possibility is discussed on the role of telomer changes in the mechanism of action for cisplatin.
25. Dunham SU, Turner CJ, Lippard SJ: Solution structure of a DNA duplex containing a nitroxide spin-labeled platinum d(GpG) intrastrand cross-link refined with NMR-derived long-range electron-proton distance restraints. J Am Chem Soc 1998, 120:5395-5406.
26. Davies MS, BernersPrice SJ, Hambley TW: Rates of platination of AG and GA containing double-stranded oligonucleotides: Insights into why cisplatin binds to GG and AG sequences, but not to GA sequences in DNA. J Am Chem Soc 1998, 120:11380-11390.
27. Speelmans G, Staffhorst RWHM, Versluis K, Reedijk J, de Kruijff B: Cisplatin complexes with phosphatidylserine in membranes. Biochemistry 1997, 36:10545-10550. Pt compounds certainty do not pass cell membranes in an innocent way.
28. Reeder F, Guo Z, del S Murdoch P, Corazza A, Hambley TW, Berners-Price SJ, Chottard J-C, Sadler PJ: Platination of a GG site on single-stranded and double-stranded forms of a 14-base oligonucleotide with diaqua cisplatin followed by NMR and HPLC. Influence of the platinum ligands and base sequence on 5′-G versus 3′-G platination selectivity. Eur J Biochem 1997, 249:370-382.
29. Hambley TW, Berners-Price SJ, Davies MS, Diakos SI, Meng Er H, Fenton RR, Ling ECH, Rezler EM: Steric determinants of Pt/DNA interactions and anticancer activity. Metal Based Drugs 1998, 5:197-206. Applying severe steric effects on amine ligands, even classical structures may not be enough for activity.
30. Sandman KE, Fuhrmann P, Lippard SJ: A mechanism-based, solution-phase method for screening combinatorial mixtures of potential platinum anticancer drugs. J Biol Inorg Chem 1998, 3:74-80.
31. Sava G, Capozzi I, Clerici K, Gagliardi G, Alessio E, Mestroni G: A new Ru(III) antitumor drug, ready for clinical trials. Clin Exp Metastasis 1998, 16:371-379. An important breakthrough is described that has brought the first Ru compound to clinical trials.
32. Depenbrock H, Schmelcher S, Peter R, Keppler BK, Weirich G, Block T, Rastetter J, Hanauske AR: Preclinical activity of trans-indazolium tetrachlorobisindazoleruthenated(111)1 (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells. Eur J Cancer 1997, 33:2404-2410.
33. 3)ruthenium(III) monohydrate. Inorg Chim Acta 1998, 273:259-265.
34. 1 (relaxivity) of water. Angew Chem Int Ed Engl 1997, 36:726-728. This discribes the first success of a targeted Gd species.
35. Toth E, Connac F, Helm L, Adzamli K, Merbach AE: Direct assessment of water exchange on a Gd(III) chelate bound to a protein. J Biol Inorg Chem 1998, 3:606-613.
36. Aime S, Botta M, Crich SG, Giovenzana GB, Pagliarin R, Piccinini M, Sisti M, Terreno E: Towards MRI contrast agents of improved efficacy. NMR relaxometric investigations of the binding interaction to HSA of a novel heptadente macrocyclic triphosponate Gd(III)-complex. J Biol Inorg Chem 1997, 2:470-479.
37. Aime S, Botta M, Fasano M, Terreno E: The relaxivity increases obtained by associating biological macromolecules such as HSA with Gd complexes substituted by hydrophobic groups. Chem Soc Rev 1998, 27:19-29.
38. 3+ (M = Re, Tc) moiety for the labeling of biomolecules. Radiochim Acta 1997, 79:99-103.
39. 4)-Tc-99m, in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc 1998, 120:7987-7988. A new avenue has been opened for starting materials based on the Tc-CO complexes.
40. Spradau TW, Katzenellenbogen JA: Protein and peptide labeling with (cyclopentadienyl)tricarbonyl rhenium and technetium. Bioconj Chem 1998, 9:765-772.
41. Meegalla SK, Plossl K, Kung MP, Stevenson DA, Mu M, Kushner S, Liable Sands SL, Reingoldm AL, Kung HF: Specificity of diastereomers of Tc-99m.TRODAT-1 as dopamine transporter imaging agents. J Med Chem 1998, 41:428-436.
42. Kung HF, Meegalla SK, Kung MP, Plossl K: Development of Tc-99m-labelled complexes for imaging dopamine transporters in the brain. Trans Met Chem 1998, 23:531-536.
43. 3)-aquatrichlororuthenium(III)monohydrate. Eur J Inorg Chem 1999:213-215.
44. Li WH, Fraser SE, Meade TJ: A calcium-sensitive magnetic resonance imaging contrast agent. J Am Chem Soc 1999, 121:1413-1414.